BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23910708)

  • 1. Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)?
    Hafeez F; Neboori HJ; Harigopal M; Wu H; Haffty BG; Yang Q; Schiff D; Moran MS
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):344-8. PubMed ID: 23910708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy.
    Moran MS; Yang Q; Goyal S; Harris L; Chung G; Haffty BG
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1236-43. PubMed ID: 21093162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
    Yamazaki N; Wada N; Yamauchi C; Yoneyama K
    Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
    Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
    Millar EK; Graham PH; McNeil CM; Browne L; O'Toole SA; Boulghourjian A; Kearsley JH; Papadatos G; Delaney G; Fox C; Nasser E; Capp A; Sutherland RL
    Br J Cancer; 2011 Jul; 105(2):272-80. PubMed ID: 21712826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
    Selz J; Stevens D; Jouanneau L; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1123-32. PubMed ID: 22572073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
    Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
    World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer.
    Moran MS; Yang Q; Harris LN; Jones B; Tuck DP; Haffty BG
    Cancer; 2008 Nov; 113(9):2565-74. PubMed ID: 18816610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 18. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy.
    Neboori HJ; Haffty BG; Wu H; Yang Q; Aly A; Goyal S; Schiff D; Moran MS; Golhar R; Chen C; Moore D; Ganesan S
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e677-83. PubMed ID: 22520477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
    Goyal S; Parikh RR; Green C; Schiff D; Moran MS; Yang Q; Haffty BG
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):679-84. PubMed ID: 19464815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.